To our knowledge, this is the first randomized controlled trial (RCT) designed to evaluate the calcitriol effects on NAFLD patients with regard to different genotypes of vitamin D receptor FokI polymorphism. This evidence concerns the gene VDR and metabolic dysfunction-associated steatotic liver disease.